Golusiński Wojciech, Wegner Anna, Trzeciak Paweł, Golusiński Paweł, Sówka Marcin, Kopczyński Andrzej, Bromboszcz Małgorzata, Marszałek Andrzej
Klinika Chirurgii Głowy, Szyi i Onkologii Laryngologicznej. Uniwersytet Medyczny im. Karola Marcinkowskiego, Kierownik: prof. dr hab. Wojciech Golusiński, Poznań, Poland; Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie, Kierownik: prof. dr hab. Julian Malicki, Poznań, Poland.
Otolaryngol Pol. 2013 Sep-Oct;67(5):245-51. doi: 10.1016/j.otpol.2013.04.002. Epub 2013 Apr 11.
The incidence of the malignant tumors of the salivary glands is relatelively low. However, rapid locoregional progression, distant metastases occurrence and high local recurrence rate occurring despite radical surgical treatment, significantly affect the outcome. Malignant tumors of the salivary glands are characterized by low radiosensitivity and poor response to systemic therapy. Therefore there is a need for new targeted therapies which may improve the prognosis. In some aspects, malignant tumors of the salivary glands are similar to breast cancers. Efficacy of hormonal replacement therapy and the treatment with the monoclonal antibody (trastuzumab) in the treatment of breast cancer is well known and confirmed. Criterion determining the qualification for treatment is the presence of hormone receptors and HER2 receptors in the tumor.
The aim of this study was to evaluate the expression of estrogen receptor, progesterone receptor and HER2 in selected salivary gland malignancies.
Study group consisted of 51 patients with the salivary glands cancer. In the study group there were 42 tumors in the parotid gland, 7 tumors of the submandibular gland, 1 in the mucosa of the cheek and 1 tumor in the tongue. Histologically material comprised of muco-epidermoid carcinoma (10), adenoid-cystic carcinoma (8), salivary duct (7), adenocarcinoma (6), squamous cell carcinoma (6), mioepithelial carcinoma (5) and other (9). In all cases immunohistochemical analysis of the estrogen receptor, progesterone receptor and HER2 receptor was performed.
The expression of the estrogen receptor was found in 18% of tumors (9 patients). The expression of the progesterone receptor was found in 20% (10 patients). HER2 expression was found in 10% of tumors and was related to only one histological type of tumor - salivary duct carcinoma.
HER2 expression in malignant tumors of the salivary glands, especially in salivary duct carcinoma may be of use in future implementation of new targeted therapies based on monoclonal antibodies.
涎腺恶性肿瘤的发病率相对较低。然而，尽管进行了根治性手术治疗，但肿瘤快速的局部区域进展、远处转移的发生以及较高的局部复发率，显著影响了治疗效果。涎腺恶性肿瘤的特点是放射敏感性低且对全身治疗反应不佳。因此，需要新的靶向治疗方法来改善预后。在某些方面，涎腺恶性肿瘤与乳腺癌相似。激素替代疗法和单克隆抗体（曲妥珠单抗）治疗乳腺癌的疗效是众所周知且得到证实的。决定治疗资格的标准是肿瘤中存在激素受体和HER2受体。
本研究的目的是评估雌激素受体、孕激素受体和HER2在所选涎腺恶性肿瘤中的表达。
研究组由51例涎腺癌患者组成。研究组中，腮腺有42个肿瘤，颌下腺有7个肿瘤，颊黏膜有1个肿瘤，舌部有1个肿瘤。组织学上，材料包括黏液表皮样癌（10例）、腺样囊性癌（8例）、涎腺导管癌（7例）、腺癌（6例）、鳞状细胞癌（6例）、肌上皮癌（5例）和其他类型（9例）。所有病例均进行了雌激素受体、孕激素受体和HER2受体的免疫组织化学分析。
18%的肿瘤（9例患者）中发现雌激素受体表达。20%（10例患者）中发现孕激素受体表达。10%的肿瘤中发现HER2表达，且仅与一种组织学类型的肿瘤——涎腺导管癌有关。
涎腺恶性肿瘤中HER2的表达，尤其是在涎腺导管癌中的表达，可能有助于未来基于单克隆抗体的新靶向治疗的实施。
